微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定_老虎社区_美港股上老虎

微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定

智通财经03-18

智通财经APP讯，微创脑科学(02172)发布公告，集团自主研发的APOLLO Dream®雷帕霉素靶向洗脱支架系统(APOLLO Dream®支架系统)近期获得美国食品药品监督管理局(FDA)授予的突破性医疗器械认定，成为全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架。APOLLO Dream®支架系统专为对现有最佳药物治疗无效的症状性颅内动脉狭窄患者而设计。该系统融合靶向...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2620518239?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-18 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620518239","market":"sh","top_or_hot":-1,"title":"微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定","media":"智通财经","content":"<div>\n<p>智通财经APP讯，微创脑科学(02172)发布公告，集团自主研发的APOLLO Dream®雷帕霉素靶向洗脱支架系统(APOLLO Dream®支架系统)近期获得美国食品药品监督管理局(FDA)授予的突破性医疗器械认定，成为全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架。APOLLO Dream®支架系统专为对现有最佳药物治疗无效的症状性颅内动脉狭窄患者而设计。该系统融合靶向...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415449.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 17:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1415449.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微创脑科学(02172)发布公告，集团自主研发的APOLLO Dream®雷帕霉素靶向洗脱支架系统(APOLLO Dream®支架系统)近期获得美国食品药品监督管理局(FDA)授予的突破性医疗器械认定，成为全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架。APOLLO Dream®支架系统专为对现有最佳药物治疗无效的症状性颅内动脉狭窄患者而设计。该系统融合靶向...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415449.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1415449.html","article_id":"2620518239","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620518239","pubTimestamp":1773825636,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微创脑科学 发布公告，集团自主研发的APOLLO Dream雷帕霉素靶向洗脱支架系统近期获得美国食品药品监督管理局授予的突破性医疗器械认定，成为全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架。APOLLO Dream支架系统专为对现有最佳药物治疗无效的症状性颅内动脉狭窄患者而设计。与传统药物支架相比，APOLLO Dream支架系统能够更加精准地控制药物释放剂量，在保证疗效的同时显著降低进入人体的总药物负荷。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","LABU":"三倍做多标普生物-Direxion","BK1583":"高瓴概念","BK1574":"生物医药B类股","02172":"微创脑科学","BK1100":"医疗保健设备","09997":"康基医疗","BK4588":"碎股","09996":"沛嘉医疗-B","BK1222":"医疗保健用品","BK4585":"ETF&股票定投概念"},"translate_title":"Minimally Invasive Brain Science (02172): APOLLO Dream ® Rapamycin Targeted Elution Stent System Receives FDA Breakthrough Medical Device Designation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1.5,"09996":1.5,"LABU":1.5,"02172":1.5,"09997":1.5},"content_text":"智通财经APP讯，微创脑科学(02172)发布公告，集团自主研发的APOLLO Dream®雷帕霉素靶向洗脱支架系统(APOLLO Dream®支架系统)近期获得美国食品药品监督管理局(FDA)授予的突破性医疗器械认定，成为全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架。APOLLO Dream®支架系统专为对现有最佳药物治疗无效的症状性颅内动脉狭窄患者而设计。该系统融合靶向药物洗脱技术与优化的支架力学结构，在提供稳定血管支撑、恢复脑部血流通畅的同时，通过靶向释放雷帕霉素至血管壁抑制血管平滑肌细胞增殖，从而降低术后再狭窄风险。与传统药物支架相比，APOLLO Dream®支架系统能够更加精准地控制药物释放剂量，在保证疗效的同时显著降低进入人体的总药物负荷。其药物涂层采用可降解材料，在完成药物释放后逐步降解，有助于降低远期血栓形成风险。突破性医疗器械认定旨在授予针对严重威胁生命或导致不可逆功能损害的疾病而开发，且具有潜在显著临床优势的创新医疗技术。APOLLO Dream®支架系统是全球首个获得该项认定的神经介入领域球囊扩张、快速交换式药物洗脱支架，该认定标志着：APOLLO Dream®支架系统在颅内动脉粥样硬化性狭窄(ICAD)治疗领域的技术创新及潜在临床价值获得国际权威监管机构认可;将有助于加快该器械的临床开发与审评进程;有望填补海外药物支架治疗颅内动脉粥样硬化性狭窄的空白市场，惠及全球患者;以及为集团推进全球化战略、加速进入国际核心市场奠定了重要基础。未来，集团将持续推进APOLLO Dream®支架系统的全球临床研究及注册进程，进一步拓展公司在神经介入创新治疗领域的国际影响力，并为全球患者提供更加先进的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}